NovaBay Pharmaceuticals Inc

Type: Company
Name: NovaBay Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.novabaypharma.com/
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

NOVABAY PHARMACEUTICALS : Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay's NeutroPhase Wound Cleanser

By a News Reporter-Staff News Editor at Drug Week -- Dr. John Crew , Vascular Surgeon and Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California , has developed a procedure in which dangerous wounds, like ... [Published 4 Traders - Apr 10 2014]
First reported Mar 30 2014 - Updated Mar 30 2014 - 1 reports

NovaBay Pharmaceuticals Inc: A Timely Raise

NovaBay Pharmaceuticals Inc (AMEX:NBY) has raised $6.7m from the sale of 5.6m shares at $1.20 per share, a modest 5% discount to the previous close. We estimate end-Q114 net cash at $15m. With the option to supplement reserves through a ~$4m ATM facility ... [Published Investing.com - Mar 30 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 4 reports

Triple Amputation From Flesh-Eating Disease in the United Kingdom Highlights Importance of NovaBay’s NeutroPhase Wound Cleanser

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex Lewis, 34, went to bed ... [Published Investor's Business Daily - Mar 28 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Novabay Pharmaceutic Given Positive Rating by Edison Group Analysts (NBY)

Novabay Pharmaceutic (NYSE:NBY)The analysts wrote, "NovaBay has raised $6.7m from the sale of 5.6m shares at $1.20 per share, a modest 5% discount to the previous close. We estimate end-Q114 net cash at $15m. With the option to supplement reserves through ... [Published American Banking News - Mar 28 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

FOPO nets $6.2mm for NovaBay

NovaBay Pharmaceuticals Inc. (topical non-antibiotic antimicrobials) netted $6.2mm through the follow-on sale of 5.6mm common shares at $1.20. The company also issued 18-month warrants to buy another 1.4mm shares of common stock exercisable at $1.56 ... [Published BioPortfolio - Mar 22 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

NOVABAY PHARMACEUTICALS, INC. FILES (8-K) Disclosing Other Events

Item 8.01. Other Events.On March 19, 2014, NovaBay Pharmaceuticals, Inc. (the "Company")entered into an underwriting agreement (the "Underwriting Agreement")with Laidlaw & Company (UK) Ltd. as representative of the several... ... [Published HispanicBusiness.com - Mar 20 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 3 reports

NovaBay Pharmaceuticals announces public offering of common stock and warrants

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, is planning to offer shares of its common stock and warrants in an underwritten public offering.Laidlaw & Company (UK) ... [Published Individual.com - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 20 2014 - 6 reports

NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

(GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an underwritten public offering of an aggregate ... [Published Benzinga.com - Mar 20 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 2 reports

NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas Paulson Interviewed by Mike Elliott of CEOLIVE.TV Video Posted on InvestmentPitch.com

Vancouver, BC, March 18, 2014 - CEOLIVE.TV's Mike Elliott interviews NovaBayPharmaceuticals' (NYSE MKT:NBY) Thomas Paulson CFO. There is a growing,worldwide crisis of germ resistance to antibiotics. NovaBay Pharmaceuticals is aclinical-stage biopharmaceutical ... [Published Pharmacy Choice - Mar 18 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 3 reports

NovaBay Pharmaceuticals’ (NYSE MKT:NBY) Thomas Paulson Interviewed by Mike Elliott of CEOLIVE.TV — Video Posted on InvestmentPitch.com

– CEOLIVE.TV’s Mike Elliott interviews NovaBay Pharmaceuticals’ (NYSE MKT:NBY) Thomas Paulson CFO. There is a growing, worldwide crisis of germ resistance to antibiotics. NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ... [Published PR-Portal.com - Mar 18 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 2 reports

NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides Clinical/Business Update

NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides Clinical/Business Update ... [Published Noodls - Mar 07 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

BioNews – 03/07/14

Top News HeadlineCompanyType Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year GileadRevenue Small Biotech Recro Pharma (REPH) Secures A $30 Million IPO Feat Recro PharmaFunding Vancouver's Aquinox Pharmaceuticals ... [Published eClinical Trends - Mar 07 2014]

Quotes

...But Dr. Crew's treatment with NeutroPhase and NPWT saved Hamilton's leg. "NeutroPhase is making history," said Dr. Najafi. "We were happy to see Jared in NovaBay's headquarters offices alive and smiling."
The analysts wrote, "NovaBay has raised $6.7m from the sale of 5.6m shares at $1.20 per share, a modest 5% discount to the previous close. We estimate end-Q114 net cash at $15m. With the option to supplement reserves through a ~$4m ATM facility with Ascendiant Capital, NovaBay has financial flexibility ahead of important clinical data in mid-2014. Results from a global 450-patient Phase IIb study of its lead anti-infective agent, auriclosene, in viral conjunctivitis are due and positive data could re-rate the stock. Post-issue our valuation rises to $90m (vs $80m), or $1.76 (vs $1.75) per share."
...and we are focusing on this important product as one of QIAGEN's global growth drivers," said Peer Schatz, QIAGEN's Chief Executive Officer. "The superiority of QIAGEN's QuantiFERON technology to deliver more reliable results than the 120-year-old tuberculin skin test already is well accepted among physicians in China, paving the way for the entry of QuantiFERON-TB into this important market."
"We believe that Dr. Crew has shown that NeutroPhase will be a very important adjunctive therapy for flesh-eating disease" said Ron Najafi, Ph D , CEO of NovaBay and one of the co-authors of Dr. Crew's Lister Legacy Prize presentation

More Content

All (51) | News (31) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (13)
sort by: Date | Relevance
NOVABAY PHARMACEUTICALS : Triple Amputation Fro... [Published 4 Traders - Apr 10 2014]
SkyePharma PLC Given “Positive” Rating by Ediso... [Published Mideast Time - Apr 01 2014]
NovaBay Pharmaceuticals Inc: A Timely Raise [Published Investing.com - Mar 30 2014]
Triple Amputation From Flesh-Eating Disease in ... [Published Investor's Business Daily - Mar 28 2014]
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire Photo/Multimedia News - Mar 28 2014]
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire Health News - Mar 28 2014]
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire News with Multimedia - Mar 28 2014]
Novabay Pharmaceutic Given Positive Rating by E... [Published American Banking News - Mar 28 2014]
Reporting live from the ASCRS ReACT program in ... [Published Eye World - Mar 22 2014]
FOPO nets $6.2mm for NovaBay [Published BioPortfolio - Mar 22 2014]
QIAGEN Launches QuantiFERON-TB Gold In-Tube in ... [Published BioMedReports - Mar 21 2014]
NOVABAY PHARMACEUTICALS, INC. FILES (8-K) Discl... [Published HispanicBusiness.com - Mar 20 2014]
NovaBay Pharmaceuticals announces public offeri... [Published Individual.com - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Pricing... [Published BioSpace - Mar 20 2014]
NovaBay raises $6.7M in shelf offering [Published Seeking Alpha - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Pricing... [Published GlobeNewswire: Advertising News - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Pricing... [Published Benzinga.com - Mar 20 2014]
NovaBay Pharmaceuticals to launch public offeri... [Published Individual.com - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published Nasdaq - Mar 19 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published GlobeNewswire: Acquisitions News - Mar 19 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published Benzinga.com - Mar 19 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published Reuters - Mar 19 2014]
NovaBay Pharmaceuticals : Announces Proposed Pu... [Published 4 Traders - Mar 19 2014]
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas ... [Published Pharmacy Choice - Mar 18 2014]
NovaBay Pharmaceuticals’ (NYSE MKT:NBY) Thomas ... [Published PR-Portal.com - Mar 18 2014]
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas ... [Published Yahoo! Finance - Mar 18 2014]
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas ... [Published Individual.com - Mar 18 2014]
NovaBay Pharmaceuticals' (NYSE MKT:NBY) Thomas ... [Published SPi World News - Mar 18 2014]
Seton Medical Center Surgeon, John Crew, MD, No... [Published Benzinga.com - Mar 13 2014]
NovaBay Pharmaceuticals Reports Fourth Quarter ... [Published Noodls - Mar 07 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire Photo/Multimedia News - Mar 28 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex ...
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire Health News - Mar 28 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex ...
Triple Amputation From Flesh-Eating Disease in ... [Published Business Wire News with Multimedia - Mar 28 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY). The Daily Mirror, a British newspaper, recently reported the tragic story of a father who lost both legs, an arm and half of his face to deadly flesh-eating bacteria. Alex ...
BioNews – 03/07/14 [Published eClinical Trends - Mar 07 2014]
Top News HeadlineCompanyType Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year GileadRevenue Small Biotech Recro Pharma (REPH) Secures A $30 Million IPO Feat Recro PharmaFunding Vancouver's Aquinox Pharmaceuticals ...
BioNews – 02/17/14 [Published eClinical Trends - Feb 17 2014]
Top News HeadlineCompanyType Biotech IPOs: Class of 2014 still rolling as investors line up to cash in n/aIPOs Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone AlexionExpansion Data science consortium outlines vision for future ...
1 2

Press Releases

sort by: Date | Relevance
NovaBay Pharmaceuticals, Inc. Announces Pricing... [Published GlobeNewswire: Advertising News - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published GlobeNewswire: Acquisitions News - Mar 19 2014]
NovaBay Pharmaceuticals Reports Fourth Quarter ... [Published GlobeNewswire: Acquisitions News - Mar 07 2014]
NovaBay CEO Comments on President Obama's 'Supe... [Published GlobeNewswire: Acquisitions News - Mar 06 2014]
NovaBay Pharmaceuticals Grants Principle Busine... [Published GlobeNewswire: Acquisitions News - Feb 26 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.